A major Aussie university and ASX-listed company will deploy psychedelic drugs to treat binge-eating in a world-first clinical trial. Experimental healthcare company Tryptamine Therapeutics announced ...
Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Placement cornerstoned by Merchant Biotech Fund and biotech investor Dr Daniel Tillett, who will join the board Funds to accelerate clinical trial strategy for lead program IV-infused psilocin ...
The open-label trial will be run in partnership with Swinburne University and plans to test Tryptamine’s IV psilocin therapy TRP-8803, with supportive psychotherapy. Watch the video to hear the ...
Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback